PanCystPro Test for Pancreatic Cyst
PanCystPro™ is a cyst-fluid assay intended to aid in diagnosis and risk stratification of pancreatic cystic lesions. The test is designed to help distinguish mucinous vs non-mucinous cysts and to estimate the probability of advanced neoplasia (high-grade dysplasia or carcinoma) to support decisions on surveillance vs intervention. PanCystPro™ analyzes biomarkers in cyst fluid obtained by endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA).
The PanCystPro test uses a proprietary platform that enables ultrasensitive detection of multiple biomarkers in small volumes of pancreatic cyst fluid. This multianalyte assay utilizes a robust algorithm and features a novel protease activity assay enabling better biological insight to inform risk stratification of pancreatic cystic lesions. This assay is intended as an adjunct to imaging, cytology, cyst fluid chemistry (e.g., CEA, amylase, glucose), and clinical criteria (AGA/ACG/Fukuoka/Kyoto), not as a stand-alone diagnostic. Test is provided by Amplified Sciences, https://amplifiedsciences.com/pancystpro/
- Triage indeterminate pancreatic cysts detected on CT/MRI/EUS imaging
- Differentiate mucinous from non-mucinous lesions to guide surveillance intervals and thresholds for resection
- Estimate risk of advanced neoplasia to prioritize surgical consultation versus imaging follow-up
- Reduce unnecessary surgery in clearly low-risk lesions; prompt timely intervention in high-risk cases
Final report typically provides a categorical result (e.g., “Mucinous likely” / “non-mucinous likely”; “High-risk signature present/absent”) and/or a quantitative probability/index. Replace with the exact PanCystPro™ terminology once available.
Result consistent with MUCINOUS cyst (e.g., IPMN/MCN): Suggests higher malignant potential than SCA/pseudocyst. Manage per guidelines (e.g., consider closer surveillance; evaluate for worrisome features/high-risk stigmata; surgical consult if criteria met).
Result consistent with NON-MUCINOUS cyst (e.g., SCA/pseudocyst): Lower malignant potential; surveillance or discharge from follow-up may be appropriate depending on size/symptoms.
High-risk: advanced neoplasia signature PRESENT: Increases probability of high-grade dysplasia/carcinoma. Correlate with EUS features (enhancing mural nodule, thickened/enhancing walls, MPD dilation), serum CA 19-9, and patient factors; prompt surgical evaluation generally recommended.
High-risk: advanced neoplasia signature ABSENT: Low short-term risk; adhere to guideline-based surveillance intervals.
Indeterminate: Quality-limited: Repeat EUS-FNA or additional testing (cytology, NGS panel) may be considered.
| Comparator | Typical Interpretation |
| CEA ≥192 ng/mL | Often indicates mucinous |
| CEA <5 ng/mL | Usually non-mucinous |
| Glucose <50 mg/dL (cyst fluid) | Favors mucinous |
| Higher glucose values (cyst fluid) | Non-mucinous |
Typical comparators (for context only; not part of PanCystPro™ unless specified).
Use PanCystPro™’s own thresholds when provided.
Collection: EUS-FNA of pancreatic cyst; avoid contamination with blood/flush.
Container: Sterile, additive-free cryovial (or manufacturer-provided kit).
Minimum volume: (commonly 0.3–1.0 mL for molecular panels; specify PanCystPro™ requirement).
Processing: Keep on ice; centrifuge to remove debris per lab SOP; freeze promptly if delayed.
Interferences: Bloody/viscous samples or scant volume may limit analysis; document needle passes and volume recovered.
- Gastrointest Endosc. 2017 May;85(5):1025-1031. [PMID: 27693645]
- Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):676-689. [PMID: 31527862]
- Meeting Abstract: 2024 ASCO Gastrointestinal Cancers Symposium. Amplified Sciences PanCyst Pro Panel to accurately identify non-mucinous pancreatic cyst fluid. Abstract